Document is current

Article History

Received: 20 March 2023

Accepted: 28 May 2023

First Online: 18 July 2023

Declarations

:

: Not applicable.

: EMA is an employee of Public Health Agency of Canada (PHAC); views expressed are her own and not those of PHAC. She is Section Head for Anaphylaxis/Food Allergy, and a Member of the Board, for the Canadian Society of Allergy and Clinical Immunology. JP is Section Head for Allied Health, and a Member of the Board, for the Canadian Society of Allergy and Clinical Immunology; sits on the steering committee for Canada’s National Food Allergy Action Plan, and reports consultancy for Nutricia, Novartis and ALK-Abelló.MBS has received consultant and/or speaker fees from Medexsus, Sanofi, Miravo, Stallergens and Novartis. EL has been a member of advisory boards for Pfizer, Miravo, Medexus, Stallergenes and ALK; has provided consultant services to ALK. ESC has received research support from DBV Technologies; has been a member of advisory boards for Pfizer, Miravo, Medexus, Leo Pharma, Kaleo, DBV, AllerGenis, Sanofi Genzyme, Bausch Health, Avir Pharma, AstraZeneca, ALK; was an expert panel and coordinating committee member of the National Institute of Allergy and Infectious Diseases (NIAID)-sponsored Guidelines for Peanut Allergy Prevention; is co-lead of CPS/CSACI Food Allergy Prevention Position Statements; is on the Executive of the CSACI (Canadian Society of Allergy and Clinical Immunology); is on the Executive of the CPS (Canadian Paediatric Society) Allergy Section; and is a member of the healthcare advisory board for Food Allergy Canada.